{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:19:09Z","timestamp":1769098749256,"version":"3.49.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.16058","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T15:32:47Z","timestamp":1654875167000},"page":"e2216058","source":"Crossref","is-referenced-by-count":15,"title":["Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022"],"prefix":"10.1001","volume":"5","author":[{"given":"Idine","family":"Mousavi","sequence":"first","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[{"name":"Department of Oncology, Geneva University Hospital, Geneva, Switzerland"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"3","key":"zoi220467r2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1377\/hlthaff.2018.05499","article-title":"National health expenditure projections, 2018-27: economic and demographic trends drive spending and enrollment growth.","volume":"38","author":"Sisko","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"zoi220467r3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions.","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"zoi220467r4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi220467r5","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1200\/JCO.2020.38.15_suppl.7071","article-title":"The correlation between clinical benefit and financial cost of cancer drugs.","volume":"38","author":"Mitchell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi220467r6","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"20","key":"zoi220467r7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi220467r8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"22","key":"zoi220467r9","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi220467r10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer.","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi220467r11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi220467r12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma.","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi220467r13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi220467r14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"10308","key":"zoi220467r15","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"zoi220467r16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer.","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi220467r17","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi220467r18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer.","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi220467r19","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"zoi220467r20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy.","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"zoi220467r21","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jamaoncol.2021.3600","article-title":"Has the current oncology value paradigm forgotten patients\u2019 time?: too little of a good thing.","volume":"7","author":"Fundytus","year":"2021","journal-title":"JAMA Oncol"},{"key":"zoi220467r1","unstructured":"McKinsey and Company. Delivering innovation: 2020 oncology market outlook. September 9, 2020. Accessed December 12, 2021. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/delivering-innovation-2020-oncology-market-outlook"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2793228\/mousavi_2022_oi_220467_1654263497.52435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T15:32:55Z","timestamp":1654875175000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2793228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.16058","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}